SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that a 1-for-8 reverse stock split of its outstanding shares of common stock will be effective at 11:59 pm Eastern Time June 16, 2025. Following the reverse stock split, the Compan ...

RAPT Therapeutics (RAPT) FY 2025 Conference June 10, 2025 09:20 AM ET Speaker0 All right. Good morning, everyone. Thanks for joining us here at the Goldman Sachs Annual Healthcare Conference. Thrilled to be joined today by the team from RAP Therapeutics. Maybe I'll let you guys introduce yourself and then we can dive into the business. Speaker1 Great. So of all, thanks Corinne for the invitation. Really appreciate it. I'm excited to be here. My name is Brian Wong. I'm the CEO and President of Wrap Therapeut ...

Rapt Therapeutics (RAPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Delaware 47-3313701 (State or other jurisdiction of incorporation or organization) 561 Eccles Avenue, South San Francisco, California 94080 (Address of principal executive offices) (Zip Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exhibit 99.1 RAPT Therapeutics Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif. – May 8, 2025 – RAPT Therapeutics, Inc. (Nasdaq: RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. "The year is off to a great start. We believe RPT904 ...

SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. “The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat p ...

SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind fr ...

Core Insights - RAPT Therapeutics has appointed Dr. Jessica Savage as Vice President of Clinical Development to lead the development of RPT904, a monoclonal antibody targeting free human immunoglobulin E (IgE) for allergic diseases [1][2] - The company plans to initiate a Phase 2b clinical trial for RPT904 in food allergy in the second half of 2025, aiming to address a significant unmet need in this area [2][3] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases, leveraging proprietary expertise in immunology [4] Leadership and Expertise - Dr. Jessica Savage brings extensive experience in clinical development, particularly in food allergy, having held significant roles at prestigious institutions and companies [3] - Her previous experience includes leading clinical development strategies for various therapies at Alexion and contributing to multiple New Drug Applications (NDAs) at other pharmaceutical companies [3]

Core Viewpoint - RAPT Therapeutics, Inc. is actively engaging with investors through participation in multiple healthcare conferences in March 2025, highlighting its focus on immunology-based therapies for inflammatory and immunological diseases [1][3]. Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of novel therapies aimed at treating patients with inflammatory and immunological diseases [2]. - The company leverages proprietary expertise in immunology to create therapies that modulate critical immune responses associated with these diseases [2]. Upcoming Events - RAPT Therapeutics will participate in the Leerink Global Healthcare Conference with a fireside chat scheduled for March 11, 2025, at 3:40 p.m. ET [3]. - The company will also take part in the Barclays 27th Annual Global Healthcare Conference, with a fireside chat on March 12, 2025, at 10:30 a.m. ET [3].

Financial Performance - The net loss for the years ended December 31, 2024 and 2023 was $129.9 million and $116.8 million, respectively, with an accumulated deficit of $614.5 million as of December 31, 2024[156]. - The company expects to continue incurring significant operating losses for the foreseeable future due to high research and development costs, with no revenue expected from product sales[157]. - The company does not expect to realize revenue from product sales in the foreseeable future until drug candidates are clinically tested, approved, and successfully marketed[177]. - The company has incurred significant net losses since inception and anticipates continuing to incur losses for the foreseeable future, which may limit the ability to utilize net operating loss carryforwards[335]. - The stock price of the company has been highly volatile, influenced by factors such as clinical trial results, regulatory developments, and market conditions[324]. - The company may need to raise additional capital through equity offerings or debt financings, which could dilute existing stockholders' ownership interests[328]. Clinical Development and Trials - The company has no products that have gained regulatory approval, and only RPT904 and tivumecirnon have been tested in humans, with no candidates advancing to late-stage development[149]. - Clinical holds were placed on the Phase 2 clinical trials of zelnecirnon in 2024 due to a serious adverse event, leading to the program's discontinuation based on FDA feedback[150]. - The company has completed a Phase 1 clinical trial for tivumecirnon and a Phase 1/2 trial in combination with pembrolizumab, but further clinical trials are needed to determine efficacy and safety[159]. - The company is facing high risks of failure in clinical development, with the potential for significant setbacks in advanced clinical trials due to lack of efficacy or safety issues[265]. - Clinical trials are expensive and can take many years to complete, with the possibility of delays due to regulatory requirements or ethical issues[269]. - The company has limited experience in managing clinical trials necessary for obtaining regulatory approvals, which typically takes many years[272]. Regulatory and Compliance Risks - The company may face additional regulatory scrutiny and potential penalties if it fails to comply with evolving government regulations[275][276]. - Regulatory approval processes are costly, time-consuming, and uncertain, with no guarantee that any drug candidates will receive the necessary approvals[270]. - The company is subject to numerous foreign regulatory requirements, which may differ significantly from U.S. regulations and could impact the approval timeline[274]. - Changes in the regulatory landscape, including the recent Supreme Court decision, could create further uncertainty for the company's operations and drug approval processes[282]. - The company may face claims from third parties alleging violations of intellectual property rights, leading to costly and time-consuming litigation[253]. Intellectual Property Risks - The company relies heavily on intellectual property rights for its drug candidates, and any failure to secure or maintain these rights could hinder its competitive position[220]. - Patent prosecution is complex and costly, and the company may not be able to effectively protect its innovations, which could impact its market position[221]. - Co-ownership of intellectual property with third parties may limit the company's ability to enforce its rights and could allow competitors to enter the market[226]. - The company may face challenges from third parties attempting to invalidate its intellectual property rights, which could impact profitability and competitive standing[237]. Operational Challenges - The company may not have the financial resources to continue development or enter new collaborations for drug candidates, which could hinder progress[154]. - The company relies on third-party organizations for clinical trials, which may lead to delays and less control over the development process[183]. - The company currently has no manufacturing capabilities and relies on sole source vendors for critical supplies[189]. - The company faces challenges in managing growth and expanding operations effectively[205]. Market and Competitive Landscape - The market may not be receptive to the company's drug candidates, which could prevent revenue generation even if regulatory approval is obtained[165]. - Intense competition exists from larger, well-capitalized companies in the biotechnology and pharmaceutical sectors[196]. - The market opportunities for drug candidates may be smaller than estimated, adversely affecting revenue generation[194]. Workforce and Human Resources - A workforce reduction impacting 47 employees, or approximately 40% of headcount, was approved in July 2024 to conserve cash resources[175]. - The ability to attract and retain qualified personnel is critical for the company's success and operational continuity[200]. - The company has 68 full-time employees as of December 31, 2024, and will need to hire more to support future development[203]. Financial and Capital Structure - The company may need to raise additional capital through public or private equity offerings, debt financings, or collaborations, with no assurance of success[174]. - Significant stockholders may exert control over corporate actions, potentially conflicting with the interests of other stockholders[332]. - The company has never declared or paid cash dividends on its capital stock, intending to retain all future earnings for business growth[339]. Environmental, Social, and Governance (ESG) Considerations - The company is subject to increasing scrutiny regarding its environmental, social, and governance (ESG) practices, which may entail additional compliance costs[322]. - The company is subject to various environmental, health, and safety regulations, and non-compliance could result in substantial fines or penalties[321]. Data Privacy and Cybersecurity - The company faces stringent data privacy and security obligations, with potential penalties including fines and disruptions to business operations[299]. - Cybersecurity threats, including ransomware attacks, pose significant risks to the company's operations and sensitive data[311]. - The company may incur costs related to notifying stakeholders of security incidents, which could lead to adverse consequences[317].